Pharmaceutical start-up MediQuest Therapeutics, which specializes on topical treatments, is getting ready to seek regulatory approval of its first commercial treatment.
In late June, the privately held Bothell firm concluded its final clinical study of a therapy to treat Raynaud’s disease, a disorder that makes the body’s extremities overreact to cold temperatures.
MediQuest expects to file an application for the new treatment with the U.S. Food and Drug Administration “sometime before the end of the year,” says Chief Executive Frederick Dechow. A new round of financing to underwrite the company’s effort lies in the “not too distant future,” he added.
The market for Raynaud’s disease treaments could be in excess of $800 million a year, Dechow said. A successful venture round — and product launch — could mean up to 100 additional jobs, Dechow said. The company currently has 28 employees.